Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GATE: GTR vs Copaxone in RRMS
NCT01489254Phase 3Completed
- Sponsor
- Synthon
- Start
- Oct 2011
- Primary completion
- Jan 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of glatiramer acetate in multiple sclerosis (MS) (3 arms), sponsored by Synthon. Primary endpoint: Number of T1-Gadolinium Enhancing Lesions at 9 months. Started Oct 2011; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01489254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01489254.